Skip to main content

Barth Syndrome

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
ElamipretidePhase 2/3Peptide1 trial
Active Trials
NCT03098797Completed12Est. Oct 2021
Stealth BioTherapeutics
1 program
ElamipretidePHASE_2_3Peptide

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioTherapeutics IncElamipretide

Clinical Trials (1)

Total enrollment: 12 patients across 1 trials

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

Start: Jul 2017Est. completion: Oct 202112 patients
Phase 2/3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.